3 Profitable Stocks Walking a Fine Line

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to avoid and some better opportunities instead.

Energizer (ENR)

Trailing 12-Month GAAP Operating Margin: 15.3%

Masterminds behind the viral Energizer Bunny mascot, Energizer (NYSE:ENR) is one of the world's largest manufacturers of batteries.

Why Are We Cautious About ENR?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Estimated sales growth of 3.4% for the next 12 months is soft and implies weaker demand
3. Free cash flow margin dropped by 3.9 percentage points over the last year, implying the company became more capital intensive as competition picked up

At $29.54 per share, Energizer trades at 8.5x forward P/E. To fully understand why you should be careful with ENR, check out our full research report (it’s free).

Meritage Homes (MTH)

Trailing 12-Month GAAP Operating Margin: 12.5%

Originally founded in 1985 in Arizona as Monterey Homes, Meritage Homes (NYSE:MTH) is a homebuilder specializing in designing and constructing energy-efficient and single-family homes in the US.

Why Do We Steer Clear of MTH?

1. Sales pipeline suggests its future revenue growth won’t meet our standards as its backlog averaged 36.5% declines over the past two years
2. 6.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. Waning returns on capital imply its previous profit engines are losing steam

Meritage Homes’s stock price of $78.78 implies a valuation ratio of 9.1x forward P/E. If you’re considering MTH for your portfolio, see our FREE research report to learn more.

Regeneron (REGN)

Trailing 12-Month GAAP Operating Margin: 27%

Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.

Why Do We Think Twice About REGN?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 5.9% over the last two years was below our standards for the healthcare sector
2. Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 21.4 percentage points
3. Eroding returns on capital suggest its historical profit centers are aging

Regeneron is trading at $560 per share, or 15.4x forward P/E. Dive into our free research report to see why there are better opportunities than REGN.

Stocks We Like More

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.